NASDAQHealth CareBiotechnologySnapshot 2026-07-23
Reading VSTM? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. VSTM is in the healthcare sector, focusing on advancing its clinical programs and commercial launches, but it faces challenges with operating losses and cash burn.
The market currently reflects a low level of fragility, indicating that investors are not overly concerned about immediate threats. However, VSTM trades at a premium compared to its peers, suggesting that some expectations for future performance are already incorporated into its valuation.
Management is actively pursuing clinical trials for VS-7375 and has shown some success with the commercial launch of AVMAPKI FAKZYNJA CO-PACK. However, the company continues to experience increasing operating losses and cash burn, which could impact its financial health in the near term.
The thesis hinges on the performance of VSTM's clinical trials and the success of its commercial products. Additionally, the broader healthcare sector's performance, particularly the results of major peers, will be critical in influencing VSTM's trajectory.
Over the next 1 to 3 years, VSTM's outlook will depend on its ability to manage losses while advancing its clinical and commercial initiatives. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Hitting the revenue goal of $17.5 million shows progress in business efforts.
Confirms:AVMAPKI FAKZYNJA CO-PACK made over $17.5 million in revenue in Q4 2025.
Disproves:Revenue falls significantly short of the $17.5 million target.
Why it matters: The earnings report will show if Verastem is improving its financial situation. Investors will look for signs of progress.
Confirms one read:The earnings report shows revenue growth or smaller losses compared to last quarter.
Confirms the other:The earnings report shows more losses or no change in revenue.
Why it matters: What management decides to do with money can affect the company's growth. A change may show a new path.
Confirms one read:Management has a new plan for spending money. This plan focuses on growth and investment.
Confirms the other:Management sticks with the current plan for spending money without changes.
Why it matters: Positive data from this trial could boost confidence in VS-7375 for treating KRAS G12D tumors.
Confirms:Early data shows strong results in patients with KRAS G12D-mutated tumors.
Disproves:Data shows no big problems with effectiveness or safety in the trial.
Why it matters: If the healthcare sector shows renewed revenue growth, it may help Verastem's performance. This could signal a better environment for the company.
Confirms:Healthcare sector revenue growth speeds up again toward its past highs.
Disproves:Healthcare sector revenue growth keeps slowing down or stays the same.
Why it matters: Lower losses would show better cost control and efficiency.
Confirms:Operating losses drop from -$44.9M in 2026-Q1.
Disproves:Operating losses remain at or worsen from -$44.9M in 2026-Q1.
Why it matters: Final results will show if the drug combination works for pancreatic cancer. Good results could help with more development and partnerships.
Confirms:The final overall survival rate from the RAMP 205 trial shows an improvement over 86%.
Disproves:Overall survival rate does not improve or declines from the current 86%.
Why it matters: Starting these trials would show progress in targeting KRAS G12D tumors. This is a key goal.
Confirms:Management announces initiation of three Phase 3 trials for VS-7375 by 1H 2027.
Disproves:No announcement of trial initiation by mid-2027.
Why it matters: This partnership could help develop VS-7375 and create more market chances.
Confirms:Announcement of a formal agreement with Erasca, Inc. regarding VS-7375.
Disproves:No updates or delays in forming the partnership with Erasca, Inc.
